CTRI/2014/08/004893已完成3 期
A phase III study to evaluate immune non inferiority and safety of the All in One liquid formulation of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV) to a licensed vaccine RotaTeq when administered as three dose series to Indian infants concomitantly with other routinely recommended vaccines for the age.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All infants must fulfill all of the following criteria in order to be eligible for the trial enrollment
- •Healthy infants, of either sex, 6-8 weeks of age at time of enrollment;
- •Born after a gestational period of >=36 weeks with birth weight >= 2 kg;
- •Father, mother or other legally acceptable representative (guardian) properly informed about the study and having signed the informed consent form (ICF). In case of father, mother or other legally acceptable representative (guardian) being unable to read or write, having the ICF explained to them in the presence of an impartial witness and the witness having signed the ICF.
- •Infant, parent or guardian available for the entire period of the study and reachable by study staff for post-vaccination follow-up.
排除标准
- •Any infant fulfilling any of the following criteria is to be excluded from the trial enrollment
- •History of congenital abdominal disorders, intussusception, or abdominal surgery;
- •Infants exhibiting signs of severe malnutrition;
- •Known or suspected impairment of immunological function in subject or immediate family;
- •Developmental delay or Neurological disorder;
- •Known hypersensitivity to any component of the study vaccines or any history of allergic reaction in past;
- •Prior receipt of any rotavirus vaccine;
- •Prior receipt of any dose of Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib or polio virus containing vaccine(s). Birth dose of Hepatitis B,BCG and Oral Polio Vaccine is allowed to be administered to the infants as per the local immunization practices. Oral Polio Vaccines administered as a part of the National Pulse Polio Program are allowed to be administered to the infants.
- •History of known rotavirus disease, chronic diarrhea, or failure to thrive;
- •Clinical evidence of active gastrointestinal illness including ongoing diarrheal episode (infants with GERD can participate in the study as long as the condition is well controlled with or without medication);
- •Receipt of any IM, oral, or IV corticosteroid treatment in the past 30 days (infants on inhaled steroids may be permitted to participate in the study);
- •Infants residing in a household with an immuno-compromised person (e.g., individuals with a congenital immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkinâ??s disease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome, organ or bone marrow transplantation, or those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids);
- •Infants already laboratory confirmed or suspected to be HIV, HBV or HCV positive from the available clinical history or born to mothers known to be HIV, HBV, or HCV positive (no specific screening for the purpose of the study would be carried out);
- •Prior receipt of a blood transfusion or blood products, including immunoglobulins, in the past 4 weeks which might interfere with the assessment of the immune response;
- •Any infants who cannot be adequately followed for safety by a home visit;
- •Any conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives;
- •Parent/s or guardian of infant unable to maintain symptom diary or note the AEs and temperature in native language for subsequent transfer into symptom diary with help of the site study team;
- •Participation in another clinical trial investigating a vaccine, drug, medical device or medicinal procedure in the 4 weeks preceding the trial vaccination;
- •Planned participation in another clinical trial during the present trial period;
- •Parents/ Guardians/ Legally Accepted Representatives identified as employees of the investigator, with direct involvement in the proposed study or studies under the direction of that investigator as well as children, adopted or natural, of the employees or Investigator.
- •Parents/ Guardians/ Legally Accepted Representatives unwilling to provide consent for Audio Visual recording of the informed consent process.
研究者
相似试验
进行中（未招募）
不适用
A study to assess the immunogenicity and safety of PCV-13 during adjuvant chemotherapyNeoplasmsKCT0003379Chonnam National University Hospital Hwasun Hospital92
进行中（未招募）
1 期
Immunogenicity and safety of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTPa-IPV/Hib) conjugate vaccine.EUCTR2013-005577-43-Outside-EU/EEAGlaxoSmithKline Biologicals235
已完成
3 期
A clinical study on Pentavalent vaccineCTRI/2015/06/005837Shantha Biotechnics Private Limited1,040
尚未招募
3 期
A Phase III Study to Evaluate the Immunogenicity and Safety of Typbar TCV Typhoid Vaccine in Adults greater than 65 Years.CTRI/2024/06/069638Bharat Biotech International Limited
进行中（未招募）
不适用
A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influspit SSW®) 2006/2007 in people aged 18 years or above - Flu-063EUCTR2006-001918-33-DEGlaxoSmithKline Biologicals120